parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in neutrophils	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	6 Parkinson's papers of 276	0.74
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 7371

CLEC7A in dopamine neurons, braak-0.17 (p 0.670) → +0.14 (p 0.722)receipt 7379
CLEC7A in microglia, braak-0.04 (p 0.926) → +0.31 (p 0.422)receipt 7378

receipt 7379: CLEC7A in dopamine neurons, braak

power: full sample -0.09 (p 0.722, n 18), 95% CI -0.53 to +0.39. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.13 (p 0.615, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.04 (p 0.874, n 18). could be the mix.
skeptic: leave-one-out range -0.22 to +0.00, sign flips 2; without severely affected donors -0.09 (p 0.722, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CLEC7A in dopamine neurons.

case closed: nothing better to follow up.

receipt 7378: CLEC7A in microglia, braak

power: full sample -0.09 (p 0.735, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.15 (p 0.555, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.03 (p 0.894, n 18). could be the mix.
skeptic: leave-one-out range -0.23 to +0.02, sign flips 1; without severely affected donors -0.09 (p 0.735, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CLEC7A in microglia.

case closed: nothing better to follow up.

loading the receipts